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Abstract
Despite extensive research during the last few decades, the etiology of schizophrenia remains unclear.
Evidence of both genetic and environmental influences in the developmental profile of schizophrenia has
grown, and due to the complexity of this disorder, a polygenic aspect has been associated with this
neuropsychiatric pathology. Unfortunately, no diagnostic strategies based on biological measurement or
genetic testing is currently available for schizophrenia. Gene-expression profiling and recent protein
studies have shown a decrease in the expression of ubiquitin pathway proteins in the prefrontal cortex of
schizophrenia patients. We have examined single nucleotide polymorphisms (or SNPs) within three genes
from the ubiquitin protein system: the ubiquitin conjugating enzyme E2D1 (UBE2D1) gene, the E3 SUMOprotein ligase protein inhibitor of activated STAT 2 (PIAS2) gene, and the E3 ubiquitin ligase F-box and
leucine-rich repeat protein 21 (FBXL21) gene, in a Caucasian case-control population for schizophrenia.
After Bonferroni correction for multiple testing was applied, no significant associations were reported for
any of the tested SNPs. Additional genetic analyses will be necessary to fully explore the role of these
three genes in schizophrenia. Regarding the rising interest in ubiquitin-related proteins as a therapeutic
target in other pathologies such as cancer, further research into the role of ubiquitin pathways in
schizophrenia seems topical and timely.

Disciplines
Medicine and Health Sciences | Social and Behavioral Sciences

Publication Details
Andrews, J. L. & Fernandez-Enright, F. (2014). Investigation of genetic variants in ubiquitin enzyme genes
involved in the modulation of neurodevelopmental processes: a role in schizophrenia susceptibility?.
Genetics Research, 96 e15-1-e15-9.

This journal article is available at Research Online: https://ro.uow.edu.au/smhpapers/2457

Andrews and Fernandez-Enright

Investigation of genetic variants in ubiquitin enzyme genes
involved in the modulation of neurodevelopmental processes: a
role in schizophrenia susceptibility?
Jessica L. Andrews a,c and Francesca Fernandez-Enright a,b,c*
a

Centre for Translational Neuroscience, Illawarra Health and Medical Research Institute,

Faculty of Science, Medicine and Health, University of Wollongong, New South Wales 2522,
Australia
b

School of Psychology, Faculty of Social Sciences, University of Wollongong, New South

Wales 2522, Australia
c

Schizophrenia Research Institute, 405 Liverpool Street, Darlinghurst New South Wales,

2010, Australia
Running Title: Investigation of ubiquitin genes in schizophrenia
Submission Category: Research Paper

*Corresponding author:
Dr Francesca Fernandez-Enright, Illawarra Health and Medical Research Institute, University
of Wollongong, Northfields Avenue, Wollongong, 2522, NSW, Australia
E-mail: fernande@uow.edu.au, Tel: (+61 2) 4221 3494, Fax: (+61 2) 4221 8130

1

Andrews and Fernandez-Enright

Summary
Despite extensive research during the last decades, the etiology of schizophrenia remains
unclear. Evidence of both genetic and environmental influences in the developmental profile
of schizophrenia has grown, and due to the complexity of this disorder, a polygenic aspect
has been associated with this neuropsychiatric pathology. Unfortunately, no diagnostic
strategies based on biological measurement or genetic testing is currently available for
schizophrenia. Gene expression profiling and recent protein studies have shown a decrease in
the expression of ubiquitin pathway proteins in the prefrontal cortex of schizophrenia
patients. We have examined Single Nucleotide Polymorphisms (or SNPs) within three genes
from the ubiquitin protein system: the ubiquitin conjugating enzyme E2D1 (UBE2D1) gene,
the E3 SUMO-protein ligase protein inhibitor of activated STAT 2 (PIAS2) gene, and the E3
ubiquitin ligase F-box and leucine-rich repeat protein 21 (FBXL21) gene, in a Caucasian
case-control population for schizophrenia. After Bonferroni correction for multiple testing
was applied, no significant associations were reported for any of the tested SNPs. Additional
genetic analyses will be necessary to fully explore the role of these three genes in
schizophrenia. Regarding the rising interest of ubiquitin related proteins as a therapeutic
target in other pathologies such as cancer, further research into the role of ubiquitin pathways
in schizophrenia seem topical and timely.

Keywords: Case-control association; Schizophrenia; Single Nucleotide Polymorphisms;
Ubiquitin related genes
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1. Introduction
Episodes of mental illness may appear and disappear throughout a person’s life,
affecting around one in five individuals. Schizophrenia is a mental disorder affecting
approximately one percent of the general population and is characterized by symptoms
such as hallucinations, delusions, disorganized communication, poor planning, reduced
motivation, and blunted affect (Lewis and Lieberman, 2000; Lewis and Levitt, 2002).
Despite 50 years of research in schizophrenia, no effective approach for prevention or
cure has been produced. The etiology of this disorder remains unclear, although
research strongly points towards the interaction between genetic and environmental
influences (Tsuang, 2000; Aukes et al., 2008). Recent gene expression and protein
studies have reported an alteration of ubiquitin pathways in the brains from
schizophrenia sufferers compared to controls (Bousman et al., 2010; Rubio et al., 2013).
The ubiquitin protein system plays an essential role in the regulation of membrane and
cellular proteins, and has often been referred to as the “kiss of death” due to its labeling
of proteins for degradation by proteases (Petroski, 2008; Tai and Schuman, 2008). The
major function of the ubiquitin protein complex is to assure intracellular protein
degradation by ubiquitination; a highly complex process involving a set of successive
enzymes: E1 (ubiquitin activating enzymes), E2 (ubiquitin-conjugating enzymes), E3
(ubiquitin protein ligases), the 20S proteasome, and deubiquitinating enzymes (Yi and
Ehlers, 2007). Ubiquitin is first activated by E1 ubiquitin-activating enzymes, before
being transferred to its active site, the amino acid cysteine. This transfer requires ATP,
making the process energy-dependent. The ubiquitin molecule is then passed on to the
second enzymes within the complex, E2 (ubiquitin-conjugating enzymes), before
reaching the final group of enzymes, the E3 ubiquitin protein ligases, which recognize
and bind the target substrate and labels it with the ubiquitin. This process can be
3
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repeated until a short chain is formed, with three or more ubiquitin molecules usually
targeting the protein to the proteasome, where the degradation occurs. Both E2 and E3
proteins exist as large families: more than 35 E2s and 600 E3s have been identified so
far, resulting in highly complex combinations of E2s with different E3 proteins defining
the substrate specificity. Defects in this ubiquitin-dependent protein degradation have
been implicated in the etiology of neurodegenerative diseases, metabolic disorders,
cancer (Weathington and Mallampalli, 2014), developmental deficiency, immunity
pathologies (Sakamoto, 2002; Pagano and Benmaamar, 2003) and schizophrenia.
We have focused our analysis on three genes coding for ubiquitin related proteins (the
ubiquitin conjugating enzyme E2D1 (UBE2D1), the E3 SUMO-protein ligase protein
inhibitor of activated STAT 2 (PIAS2) and the E3 ubiquitin ligase F-box and leucinerich repeat protein 21 (FBXL21), which is a SKP1-cullin-F-box (SCF) protein,
implicated in the regulation of the p53 pathway (Figure 1). The p53 pathway plays an
essential role in the modulation of neurodevelopmental processes (including cerebral
vascularization and neurogenesis) and/or to neurodevelopmental disorders such as
schizophrenia. Due to their previous association in different reports and populations
(Chen et al., 2008; Middleton et al., 2002), we analyzed a set of potential Single
Nucleotide Polymorphisms (SNPs) in the UBE2D1 (coding for E2D1 protein), PIAS2
(coding for the protein inhibitor of activated STAT 2) and FBXL21 gene (coding for Fbox and leucine-rich repeat protein 21) in the largest schizophrenia case-control
Caucasian population collected in Australia to examine their potential associations with
this devastating neurodevelopmental disorder.
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2. Materials and methods
(i)

DNA samples

DNA samples were obtained from the Australian Schizophrenia Research Bank
(ASRB). Subjects with schizophrenia were identified using the Diagnostic and
Statistical Manual of Mental Disorders IV criteria. All samples were from Caucasian
volunteers. Subjects were matched for gender and age. The complete sample consisted
of 268 schizophrenia cases, comprised of 186 males and 82 females, with an average
age of 38.86±11.01 years; and 268 matched controls, comprised of 169 males and 99
females, with an average age of 38.56±12.57 years, with no prior history of mental
disorders. After a complete description of the study to the subjects, written informed
consent was obtained. This study was approved by, and conducted according to the
guidelines of the University of Wollongong Human Research Ethics Committee
(HE10/161).
(ii)

SNP genotyping

SNPs within the UBE2D1 (rs11006122 and rs1905455), PIAS2 (rs8094449,
rs10502878, rs11876274, and rs56352844) and FBXL21 (rs1859427 and rs6861170)
genes were tested in our Caucasian schizophrenia case-control population. The selection
of these SNPs was based on their previous associations with schizophrenia and/or other
disorders, and on their Minor Allele Frequencies (MAF) reported in Caucasian
populations (MAF>15%) using HapMap data (http://hapmap.ncbi.nlm.nih.gov). Highthroughput SNP genotyping was performed using the MassARRAY® genotyping assay
(Sequenom, Inc., San Diego, CA, USA), with the analysis performed by matrix-assisted
laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). PCR

5

Andrews and Fernandez-Enright

and extension primer design, selection and multiplexing were performed using
MassARRAY® Designer Software (Sequenom, Inc., San Diego, CA, USA).
(iii)

Statistical analysis

Power calculations indicated that for the smaller of the two cohorts, a sample size of
204 cases (408 alleles) with a minor allele frequency of 0.2; has >90% a priori power to
detect a significant allelic association conferring an odds ratio of 1.5 or greater. The
distribution of all tested SNPs did not deviate significantly from Hardy Weinberg
Equilibrium (HWE) (p>0.05), except for UBE2D1 (rs1905455, p=1.88x10-17) which
was then excluded from further analysis. To detect associations between each SNP and
schizophrenia, chi-square (χ2) analysis was performed to test for significant differences
in allele and genotype frequencies between the case and control groups. The
significance for all statistical tests was set to p<0.05 and values p<0.10 were described
as trends. Data are expressed as specific counts for alleles and genotypes. Due to
multiple testing in the SNP analysis, a standard Bonferroni-corrected p-value of 0.007
(0.05/7) was required to give a 95% probability of correctly concluding not to reject the
null hypothesis in the χ2 test.
3. Results
Two SNPs within UBE2D1, four SNPs in PIAS2 and two SNPs within FBXL21 were
analyzed for association with schizophrenia in a large Australian Caucasian population
(268 schizophrenia patients versus 268 matched controls with no prior history of mental
disorders).
Following Bonferroni correction for multiple comparisons there were no significant
associations between the allelic frequency of any of the tested SNPs (UBE2D1

6

Andrews and Fernandez-Enright

rs11006122, PIAS2 rs8094449, rs10502878, rs11876274, and rs56352844; FBXL21
rs1859427 and rs6861170) and schizophrenia (0.08≤p≤0.92; Tables 2, 3 and 4
respectively). In addition there were no genotypic associations between any of the tested
SNPs and schizophrenia following Bonferroni correction (0.17≤p≤0.71; Tables 2, 3 and
4). Further, analysis of each of the genetic markers by gender revealed no significant
allelic or genotypic associations with any of these genetic markers and either gender
(0.08≤p≤1.00; Tables 2, 3 and 4). Interestingly, the demographics of our tested
population (Table 1) revealed that a large percentage of our schizophrenia subjects had
a family history of mental disorders, twice as many as the control group. χ2 analysis
revealed that both of the FBXL21 genetic markers rs1859427 and rs6861170 had a
significant genotypic association with schizophrenia in the subjects whose mother
(rs1859427: χ2=8.35, p=0.01; rs6861170: χ2=8.20, p=0.01) and/or father (rs1859427:
χ2=16.80, p<0.001; rs6861170: χ2=15.54, p<0.001) had a history of mental disorders.
None of the other SNPs from any of the other genes studied had any significant
associations with schizophrenia in subjects who had a family history of mental disorders
(0.10≤χ2≤4.17, 0.12≤p≤0.95). In addition, a large percentage of subjects from both
tested groups experienced some form of self-reported childhood trauma, including but
not limited to neglect, physical abuse, sexual abuse, and post-traumatic stress, with a
larger number of schizophrenia subjects (41.0%) having a traumatic childhood
compared to the control group (22.4%). Again, χ2 analysis revealed that both of the
FBXL21 genetic markers rs1859427 and rs6861170 had a significant genotypic
association with schizophrenia in the subjects who experienced childhood trauma
(rs1859427: χ2=9.67, p=0.007; rs6861170: χ2=7.75, p=0.02). Again, none of the other
SNPs analyzed had any significant associations with schizophrenia in subjects who
experienced trauma during childhood (1.49≤χ2≤4.34, 0.11≤p≤0.47).
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4. Discussion
We have investigated the association of three genes from the ubiquitin protein system
involved in the regulation of the p53 pathway in a large Australian Caucasian casecontrol schizophrenia population. We did not report any significant associations with
schizophrenia for any of the tested SNPs in the UBE2D1, PIAS2 and FBXL21 genes in
our population.
There is little information in the literature regarding association studies for our tested
genes. Only the FBXL21 gene has been previously studied in two independent Irish
populations, one corresponding to a high density of schizophrenia in Irish families
(1,350 subjects from 273 families) and the other was a large Irish case-control
population (814 cases versus. 625 controls) (Chen et al., 2008). Chen et. al. found
rs1859427 and rs6861170 to be significantly associated with schizophrenia within their
case-control population, and significance was maintained even after correction for
multiple testing (p=0.01967 for both markers) (Chen et al., 2008). The MAF for both
rs1859427 and rs6861170 FBXL21 markers were very similar in the schizophrenia
group for both the present study (MAF=0.32 for both markers) and in the Chen et. al.
study (MAF=0.27). This suggests that there is likely to be a difference between the
genotyping frequencies in the schizophrenia groups and/or frequencies in the control
group between our study and the Chen et. al. study.
Interestingly, when we factor into our analysis the subjects who experienced some sort
of trauma during childhood, the FBXL21 SNPs showed a significant association with
schizophrenia among the tested SNPs (Table 5), however none of the other tested SNPs
in any of the other tested genes had any significant associations in schizophrenia
subjects who self-reported any traumatic childhood experiences. Differential epigenetic
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gene regulation in relation to traumatic childhood experiences has only ever been
reported for one ubiquitin E3 ligase (Mahogunin Ring Finger 1 or MGRN1) in women
with fibromyalgia who had experienced traumatic childhood events (Menzies et al.,
2013). This suggests that adverse childhood experiences are able to induce genetic and
epigenetic variations in ubiquitin protein genes responding to stressful conditions such
as Ring Type E3 ubiquitin ligase and F-box proteins (Hermand, 2006; Hua and Vierstra,
2011). A number of studies have shown strong associations between negative childhood
experiences and adult psychiatric illnesses, in particular depression, psychosis and
schizophrenia (Edwards et al., 2003; Kelleher et al., 2008; Lu et al., 2008). When we
accounted for a family history of mental illness from either the mother and/or father
within our tested population, we found a positive association between the FBXL21
SNPs and schizophrenia (Table 5); but again there were no significant associations with
any of the other tested SNPs in the tested genes in schizophrenia subjects who had a
family history of mental illness, suggesting an inheritance for the FBXL21 genetic
markers in the context of psychiatric disorders. This is in line with the Chen et. al study
which showed that the haplotype of FBXL21 markers rs1859472 and rs6861170 were
over-transmitted in the Irish study of high density schizophrenia families.
As mentioned above, the FBXL21 gene encodes for an E3 ubiquitin ligase F-box protein
in the SKP1-cullin-F-box (SCF) complex. The FBXL21 protein is known to be able to
stabilize cryptochrome (CRY) proteins CRY1 and CRY2, which are implicated in
regulating mammalian circadian rhythms (Hirano et al., 2013). In fact, the FBXL21
protein was reported to antagonize the FBXL3 protein, another F-box-type E3 ligase,
which ubiquitinates CRY proteins and mediates their degradation (Hirano et al., 2013).
By attenuating the destabilizing action of FBXL3 on CRY proteins, FBXL21 expression
allows for an adapted regulation of circadian rhythm gene transcription by CRY
9
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proteins according to the circadian cycle. Furthermore, the circadian pattern of FBXL21
expression in the mouse suprachiasmatic nucleus (region responsible for controlling
circadian rhythm) is reminiscent of the expression pattern seen for other circadian
pacemaker genes such as Period 1 (PER1) (Dardente et al., 2008). Mutations in either
the FBXL21 or FBXL3 genes can lead to a dysfunction of circadian rhythm oscillations
and lead to significant behavioral disturbances in individuals and alterations in their
sleeping patterns; moreover the absence of FBXL21 causes a short-period phenotype in
both mice and cells (Hirano et al., 2013; Yoo et al., 2013). Interestingly, schizophrenia
patients have been reported to have intrinsically unstable circadian oscillators. A study
by Bromundt et. al. recently provided important new information concerning the link
between impairments in neuropsychological function and disrupted circadian rhythms in
schizophrenia. (Bromundt et al., 2011); which is further supported by a microarray
study which found a significant downregulation of the circadian pacemaker gene PER1
in the postmortem temporal cortex of schizophrenia patients compared to healthy
controls (Aston et al., 2004). Furthermore, an animal model study has shown
dysfunction in the synchronization of circadian rhythms between brain cell networks
involved in sleep–wake regulation and cognition (Dudley et al., 2003). Overall this
suggests that alterations in circadian rhythms are present in schizophrenia, and that
polymorphisms in the FBXL21 gene in addition to the FBX3 gene, could be involved in
the circadian cycle disturbances that have been observed in schizophrenia (Mansour et
al., 2009).
The FBXL21 gene is located on Chromosome 5q31, a region that has previously been
shown to contribute to the susceptibility for schizophrenia in both German and Israeli
pedigree families (lod score 1.8) (Schwab et al., 1997). Putative loci associated with
psychosis in bipolar disorder pedigrees were characterized in the chromosomic region
10
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18q21, which includes the locus for the PIAS2 gene (Park et al., 1995). This region has
also been suggested to be an influential genetic loci, common to both schizophrenia and
bipolar disorders, depending on polygenic influence and critical environmental factors
(Mors et al., 1997). Unfortunately, we did not report any significant associations
between the tested SNPs (promoter and intron variants) in the PIAS2 gene with
schizophrenia, suggesting that other genetic markers within this gene may be involved.
Similarly, the genetic polymorphisms analyzed within the UBE2D1 gene (located in the
promoter region) were not associated with schizophrenia in our tested population. The
UBE2D1

gene

is

located

at

the

chromosomic

region

10q21.1

(http://www.ncbi.nlm.nih.gov/gene/7321). This region includes the Ankyrin 3 (ANK3)
gene, previously associated with schizophrenia by a number of studies that found the
rs10761482 SNP to be associated with schizophrenia in a large European population as
well as Han Chinese populations (Gella et al., 2011; Yuan et al., 2012).
Due to its early expression in brain development and its key role in genomic stability as
well as apoptotic process in brain cells, the p53 pathway plays an essential role in the
modulation of neurodevelopmental processes, including those within the schizophrenia
pathophysiology. Interestingly a reduced risk of cancer has been observed in individuals
with schizophrenia during the last decade; considering the significant role p53 plays in
the progression of cancer, this suggests a significant role of p53 in schizophrenia.
Previous p53 polymorphisms were found to be associated with schizophrenia in both
Chinese and Caucasian case-control populations and in family studies (Yang et al.,
2004; Ni et al., 2005). It is thought that the regulation of p53 expression by ubiquitin
degradation may play an important role in schizophrenia pathophysiology. Although the
present study did not examine polymorphisms within p53, all of the genes examined are
involved in p53 signaling. While we did not find any significant associations between
11
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any of the tested polymorphisms and schizophrenia, replicating our study in a larger
population and/or testing additional polymorphisms within the same genes will add to,
and allow for further exploration of the role of the tested ubiquitin related genes in the
genetic vulnerability of schizophrenia.
Our study reports the analysis of potential SNPs in three candidate genes from the
ubiquitin protein system in a large Australian case-control schizophrenia population.
Due to the limited information available on the role of E2 ubiquitin conjugating
enzymes and E3 ubiquitin ligases in schizophrenia, in addition to the increasing variety
of these groups of proteins, additional studies will be necessary to further examine the
role of these ubiquitin proteins in the genetics of schizophrenia. A growing interest has
recently emerged which is targeting ubiquitin related proteins in the treatment of cancer
and inflammatory related diseases. Keeping in mind the paradoxical relationship
between cancer and schizophrenia, the ubiquitin protein systems seem to be a good
candidate to further analyze in the genetics and therapy for schizophrenia.
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Table 1. Subject Demographics for Control (n = 268) and Schizophrenia Subjects (n =
268).
Gender
Female
Male
Age at assessment (years)
Female
Male
Family history of mental disorders
Mother
Father
Traumatic childhood experience

Control subjects n (%)

Schizophrenia subjects n (%)

99 (37%)
169 (63%)

82 (30.6%)
186 (69.4%)

32.19
42.22

40.48
38.14

41 (15.3%)
49 (18.3%)
60 (22.4%)

95 (35.5%)
106 (39.6%)
110 (41.0%)
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Table 2. Allelic and genotypic distributions for UBE2D1 genetic marker in
schizophrenia subjects and controls.
UBE2D1
Schizophrenia
Male
Female
Control
Male
Female
Total case vs. control
Male case vs. control
Female case vs. control

N
(alleles)
rs11006122
264
190
74
368
232
136

Alleles
C

T

CC

150 (56.8%)
106 (55.8%)
44 (59.5%)
217 (59.0%)
134 (57.8%)
83 (61.0%)
χ2 = 0.29
χ2 = 0.17
χ2 = 0.05

114 (43.2%)
84 (44.2%)
30 (40.5%)
151 (41.0%)
98 (42.2%)
53 (39.0%)
p = 0.58
p = 0.68
p = 0.82

45 (34.1%)
30 (31.6%)
15 (40.5%)
63 (34.2%)
40 (34.5%)
23 (33.9%)

Genotypes
CT

TT

60 (45.5%)
46 (48.4%)
14 (37.8%)
91 (49.5%)
54 (46.6%)
37 (54.4%)
χ2 = 0.99
χ2 = 0.20
χ2 = 3.18

27 (20.4%)
19 (20.0%)
8 (21.6%)
30 (16.3%)
22 (18.9%)
8 (11.7%)
p = 0.61
p = 0.90
p = 0.20
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Table 3. Allelic and genotypic distributions for PIAS2 genetic markers in schizophrenia
subjects and controls.
PIAS2
Schizophrenia
Male
Female
Control
Male
Female
Total case vs. control
Male case vs. control
Female case vs. control
PIAS2
Schizophrenia
Male
Female
Control
Male
Female
Total case vs. control
Male case vs. control
Female case vs. Control
PIAS2
Schizophrenia
Male
Female
Control
Male
Female
Total case vs. control
Male case vs. control
Female case vs. control
PIAS2
Schizophrenia
Male
Female
Control
Male
Female
Total case vs. control
Male case vs. control
Female case vs. control

N
(alleles)
rs8094449
442
314
128
498
314
184

N
(alleles)
rs10502878
204
150
54
324
210
114

N
(alleles)
rs11876274
278
196
82
382
238
144

N
(alleles)
rs56352844
206
154
52
328
212
116

Alleles
G

A

GG

423 (95.7%)
300 (95.5%)
123 (96.1%)
471 (94.6%)
300 (95.5%)
171 (92.9%)
χ2 = 0.63
χ2 = 0.00
χ2 = 0.39

19 (4.3%)
14 (4.5%)
5 (3.9%)
27 (5.4%)
14 (4.5%)
13 (7.1%)
p = 0.42
p = 1.00
p = 0.24

202 (91.4%)
143 (91.1%)
59 (92.2%)
223 (89.6%)
143 (91.1%)
80 (87.0%)

Alleles
C

T

CC

160 (78.4%)
117 (78.0%)
43 (79.6%)
273 (84.3%)
173 (82.4%)
100 (87.7%)
χ2 = 2.88
χ2 = 1.07
χ2 = 1.89

44 (21.6%)
33 (22.0%)
11 (20.4%)
51 (15.7%)
37 (17.6%)
14 (12.3%)
p = 0.08
p = 0.30
p = 0.16

62 (60.8%)
46 (61.3%)
16 (59.3%)
113 (69.8%)
69 (65.7%)
44 (77.2%)

Alleles
T

C

TT

260 (93.5%)
184 (93.9%)
76 (92.7%)
354 (92.7%)
224 (94.1%)
130 (90.3%)
χ2 = 0.18
χ2 = 0.01
χ2 = 0.37

18 (6.5%)
12 (6.2%)
6 (7.3%)
28 (7.3%)
14 (5.9%)
14 (9.7%)
p = 0.67
p = 0.91
p = 0.54

121 (87.1%)
86 (87.8%)
35 (85.4%)
164 (85.9%)
105 (88.2%)
59 (81.9%)

Alleles
A

G

AA

193 (93.7%)
145 (94.2%)
48 (92.3%)
308 (93.9%)
200 (94.3%)
108 (93.1%)
χ2 = 0.01
χ2 = 0.01
χ2 = 0.03

13 (6.3%)
9 (5.8%)
4 (7.3%)
20 (6.1%)
12 (5.7%)
8 (6.9%)
p = 0.92
p = 0.94
p = 0.85

90 (87.4%)
68 (88.3%)
22 (84.6%)
145 (88.4%)
94 (88.7%)
51 (88.0%)

Genotypes
GA

AA

19 (8.6%)
14 (8.9%)
5 (7.8%)
25 (10.0%)
14 (8.9%)
11 (11.9%)
χ2 = 1.19
χ2 = 0.00
χ2 = 1.44
Genotypes
CT

0 (0%)
0 (0%)
0 (0%)
1 (0.4%)
0 (0%)
1 (1.1%)
p = 0.55
p = 1.00
p = 0.48
TT

36 (35.3%)
25 (33.3%)
11 (40.7%)
47 (29.0%
35 (33.3%)
12 (42.1%)
χ2 = 3.53
χ2 = 3.15
χ2 = 3.89
Genotypes
TC

4 (3.9%)
4 (5.3%)
0 (0%)
2 (1.2%)
1 (0.9%)
1 (1.7%)
p = 0.17
p = 0.20
p = 0.14
CC

18 (12.9%)
12 (12.2%)
6 (14.6%)
26 (13.6%)
14 (11.8%)
12 (16.7%)
χ2 = 0.77
χ2 = 0.01
χ2 = 0.67
Genotypes
AG

0 (0%)
0 (0%)
0 (0%)
1 (0.5%)
0 (0%)
1 (1.4%)
p = 0.68
p = 0.99
p = 0.71
GG

13 (12.6%)
9 (11.7%)
4 (15.4%)
18 (11.0%)
12 (11.3%)
6 (10.3%)
χ2 = 0.78
χ2 = 0.01
χ2 = 0.85
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0 (0%)
0 (0%)
0 (0%)
1 (0.6%)
0 (0%)
1 (1.7%)
p = 0.67
p = 0.99
p = 0.65

Table 4. Allelic and genotypic distributions for FBXL21 genetic marker in
schizophrenia subjects and controls.
FBXL21
Schizophrenia
Male
Female
Control
Male
Female
Total case vs. control
Male case vs. control
Female case vs. control
FBXL21
Schizophrenia
Male
Female
Control
Male
Female
Total case vs. control
Male case vs. control
Female case vs. control

N
(alleles)
rs1859427
266
192
74
374
234
140

N
(alleles)
rs6861170
268
192
76
372
234
138

Alleles
G

A

GG

179 (67.3%)
129 (67.2%)
50 (67.6%)
264 (70.6%)
166 (70.9%)
98 (70%)
χ2 = 0.79
χ2 = 0.70
χ2 = 0.02

87 (32.7%)
63 (32.8%)
24 (32.4%)
110 (29.4%)
68 (29.1%)
42 (30%)
p = 0.37
p = 0.40
p = 0.87

64 (48.1%)
45 (46.9%)
19 (51.4%)
98 (52.4%)
64 (54.7%)
34 (48.6%)

Alleles
T

G

TT

182 (67.9%)
132 (68.8%)
50 (65.8%)
264 (71.0%)
167(71.4%)
97 (70.3%)
χ2 = 0.69
χ2 = 0.35
χ2 = 0.46

86 (32.1%)
60 (31.2%)
26 (34.2%)
108 (29.0%)
67 (28.6%)
41 (29.7%)
p = 0.41
p = 0.55
p = 0.49

66 (49.3%)
47 (49.0%)
19 (50%)
98 (52.7%)
64 (54.7%)
34 (49.3%)

Genotypes
GA

AA

51 (38.3%)
39 (40.6%)
12 (32.4%)
68 (36.4%)
38 (32.5%)
30 (42.8%)
χ2 = 0.70
χ2 = 1.60
χ2 = 1.97

18 (13.6%)
12 (12.5%)
6 (16.2%)
21 (11.2%)
15 (12.8%)
6 (8.6%)
p = 0.70
p = 0.44
p = 0.37

Genotypes
TG

GG

50 (37.3%)
38 (39.6%)
12 (31.6%)
68 (36.7%)
39 (33.3%)
29 (42.0%)
χ2 = 0.66
χ2 = 0.92
χ2 = 4.84

18 (13.4%)
11 (11.4%)
7 (18.4%)
20 (10.6%)
14(12.0%)
6 (8.7%)
p = 0.71
p = 0.63
p = 0.08
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Table 5. Genotypic distributions for FBXL21 genetic markers in schizophrenia subjects
and controls with respect to parental history of mental health issues and traumatic
childhood experiences.
FBXL21
rs1859427
Schizophrenia
Mother mental history
Father mental history
Traumatic childhood
Control
Mother mental history
Father mental history
Traumatic childhood
Mother mental case vs. control
Father mental case vs. control
Traumatic childhood case vs. control
FBXL21
rs6861170
Schizophrenia
Mother mental history
Father mental history
Traumatic childhood
Control
Mother mental history
Father mental history
Traumatic childhood
Mother mental case vs. control
Father mental case vs. control
Traumatic childhood case vs. control

GG
64 (48.1%)
19 (46.3%)
29 (56.9%)
25 (46.3%)
98 (52.4%)
8 (29.6%)
18 (52.9%)
13 (37.1%)

TT
66 (49.3%)
20 (47.6%)
29 (54.7%)
25 (44.6%)
98 (52.7%)
9 (34.6%)
18 (54.5%)
13 (38.2%)

Genotypes
GA

AA

51 (38.3%)
19 (46.3%)
18 (35.3%)
21 (38.9%)
68 (36.4%)
14 (51.9%)
13 (38.2%)
19 (54.3%)
χ2 = 8.35
χ2 = 16.80
χ2 = 9.67

18 (13.6%)
3 (7.4%)
4 (7.8%)
8 (14.8%)
21 (11.2%)
5 (18.5%)
3 (8.8%)
3 (8.6%)
p = 0.01
p < 0.001
p = 0.007

Genotypes
TG

GG

50 (37.3%)
18 (42.9%)
18 (34.0%)
21 (37.5%)
68 (36.7%)
13 (50.0%)
13 (39.4%)
18 (52.9%)
χ2 = 8.20
χ2 =15.54
χ2 = 7.75

18 (13.4%)
4 (9.5%)
6 (11.3%)
10 (17.9%)
20 (10.6%)
4 (15.4%)
2 (6.1%)
3 (8.8%)
p = 0.01
p < 0.001
p = 0.02
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Figu
ure 1. Scheematic of thee implicatio
on of the prooteins coded
d by the gen
nes of intereest in brain developmennt.
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